New generic IM DMPA available for procurement

Jul 19, 2018 | Family Planning, Quality, WHO PQ

Mylan Laboratories Limited has received a risk category 1 ranking from the WHO Expert Review Panel for its generic intramuscular injectable, medroxyprogesterone acetate depot 150mg/ml (IM DMPA).

This is exciting news and supports the broader effort of Concept Foundation, through its funding from the Bill & Melinda Gates Foundation (BMGF), and the efforts of the wider RH community to increase access to quality assured, long acting contraceptive methods such as DMPA. Famy Care Ltd., before its acquisition by Mylan, was one of the selected companies supported by Concept Foundation from 2012 – 2015 through its program ”Addressing the barriers to making quality-assured, three monthly injectable contraception widely available”, funded by BMGF.